at2

MAT2A-IN-9, a 2-oxoquinazoline derivative, is a potent MAT2A (methionine adenylyltransferase 2A) inhibitor.MAT2A-IN-9 has antitumor activity for the treatment of lymphomas and solid tumors.

EAAT2 activator 1 (3-[(2-Chloro-6-fluorobenzyl)thio]-6-pyridin-2-ylpyridazine) is a thiopyridazine derivative that has been found to increase EAAT2 protein levels in astrocytes.

MAT2A inhibitor 4 is an inhibitor of the catalytic subunit of methionine S-adenosyltransferase-2, which is used in cancer research.

AT2R antagonist 1 is a highly selective and potent AT2R (angiotensin II AT2 receptor) ligand.AT2R antagonist 1 has a high affinity for AT2R affinity (Ki: 29 nM).AT2R antagonist 1 inhibits common drug metabolizing CYP enzymes and has high stability in human, rat, and mouse liver microsomes.AT2R antagonist 1 has a high affinity for AT2R affinity (Ki: 29 nM).AT2R antagonist 1 has a high affinity for AT2R affinity (Ki: 29 nM). It has high stability in human, rat and mouse liver microsomes.

JNJ-DGAT2-B is a selective inhibitor of Diacylglycerol acyltransferase 2.

GAT229 is a positive allosteric modulator of cannabinoid receptor 1 (CB1) and the S-(-) enantiomer of the CB1 modulator GAT211. It does not activate the receptor on its own but enhances the binding and activity of CB agonists. GAT229 (1 μM) enhances the binding of the CB1 full agonist CP 55,940 to CHO cells expressing human recombinant CB1 (hCB1), as well as the activity of 2-arachidonoyl glycerol , arachidonoyl ethanolamide , and CP 55,940 in arrestin2 recruitment assays and increases ERK1/2 and PLCβ3 phosphorylation in HEK293 cells expressing hCB1. GAT229 (1 μM) enhances depolarization-induced suppression of excitation but does not inhibit excitatory postsynaptic currents (EPSCs) in murine autaptic hippocampal neurons. GAT229 (0.2%, topical) reduces intraocular pressure by 5.8 and 7.7 mm Hg after 6 and 12 hours, respectively, in a transgenic mouse model of ocular hypertension using nose, ear, eye mutation (nee) mice.

DGAT2-IN-3 (compound 9) is an inhibitor of DGAT2 with an IC50 value of 0.4 nM. It is utilized in research related to fatty liver disease, diabetes, and cardiovascular diseases.

MAT2A-IN-19 (Compound I-3) is an inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 32.93 nM.

MAT2A-IN-16 is a MAT2A inhibitor that effectively suppresses the proliferation of MTAP- -HCT-116 cells, with an IC50 value of 20 nM.

MAT2A-IN-17 is a potent inhibitor of MAT2A, with an IC50 of less than 100 nM. MAT2A-IN-17 is applicable in cancer research.

Compound I-16 (AT2R antagonist 2) is an orally active AT2R antagonist.

GAT211 (AZ-4) is a selective and potent cannabinoid 1 receptor (CB1R) orthosteric modulator (PAM) with high affinity for cAMP and β-arrestin2.GAT211 has IOP-lowering and antipsychotic effects and can be used in the study of epilepsy.

MAT2A inhibitor 2 is an inhibitor of methionine adenosyltransferase 2A (MAT2A).

NAT2-IN-1 (APA) is a selective inhibitor of the drug metabolism enzyme N-acetyltransferase 2 (NAT2), effectively targeting and eliminating cells with reduced NAT2 activity [1].

MAT2A-IN-3, a potent MAT2A inhibitor, suppresses the proliferative activity of MTAP-deficient cancer cells and shows potential for cancer research [3=c₁(c(c(c(c(c₁cl)O)O)O)I)c₂c(NC(c(n₂)C(F)(F)F)Cl)=O].

MAT2A-IN-7, a potent inhibitor of the enzyme MAT2A, demonstrates efficacy in targeting the abnormally elevated expression of MAT2A observed in gastric, colon, liver, and pancreatic cancers. Furthermore, MAT2A-IN-7 effectively reduces the proliferative activity specifically in MTAP-deficient cancer cells, thus highlighting its potential for cancer research applications [1].

MAT2A-IN-6 is a potent inhibitor of MAT2A that reduces the proliferative activity of MTAP-deficient cancer cells, demonstrating significant research potential in cancer diseases.

MAT2A-IN-4 can be used for the cancer research that is an inhibitor of methionine adenosyltransferase 2A (MAT2A)[1].

MGAT2-IN-4 (compound 33) is a monoacylglycerol acyltransferase 2 (MGAT2) inhibitor with liver metabolic stability, applicable in obesity, diabetes, and non-alcoholic steatohepatitis (NASH) research [1].

MAT2A-IN-21 (compound 28) is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 49 nM. It selectively inhibits cancer cells with MTAP deficiency.

MGAT2-IN-1 is an orally active monoacylglycerol acyltransferase (MGAT2)inhibitor (human and mouse MGAT2 with IC50 of 7.8 and 2.4 nM , respectively).

MAT2A-IN-10 (Compound 28), an orally active inhibitor of MAT2A, exhibits an IC50 of 26 nM and is utilized in cancer research [1].

MAT2A inhibitor 3 can be used in the cancer research. MAT2A inhibitor 3 is a inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC 50 of <200 nM [1].

MAT2A Allosteric Inhibitor 2 is a potent, selective inhibitor exhibiting an IC50 of 5 nM and demonstrates nanomolar efficacy (IC50 = 5 μM) in proliferation assays utilizing the MTAP - - cell line [1].